Xlife Sciences News Today

Xlife Sciences AG / Key word: Alliance/Merger Xlife Sciences AG Announces Strategic Merger Between palleos healthcare GmbH and OCT Clinical GmbH 27.05.2024 / 07:00...

For public distribution Xlife Sciences AG Valuation Report 2023 Valuation as of December 31st 2023 Zurich /...

Xlife Sciences AG Key word Annual Results Xlife Sciences AG Publishes 2023 Annual Report 23Apr2024 0700 CETCEST Release of an ad hoc announcement pursuant to Art 53 LR The issuer is solely responsibl

Xlife Sciences AG / Key word: Annual Results Xlife Sciences AG Publishes 2023 Annual Report 23-Apr-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The...

Xlife Sciences AG / Key word: Mergers & Acquisitions/Takeover VERAXA Biotech AG acquires Synimmune GmbH to expand cancer pipeline 29-Dec-2023 / 17:45 CET/CEST Release of an ad hoc...

Xlife Sciences AG Key word Mergers & AcquisitionsTakeover VERAXA Biotech AG acquires Synimmune GmbH to expand cancer pipeline 29Dec2023 1745 CETCEST Release of an ad hoc announcement pursuant to

29.12.2023 - Xlife Sciences AG / Key word(s): Mergers & Acquisitions/Takeover VERAXA Biotech AG acquires Synimmune GmbH to expand cancer pipeline 29-Dec-2023 / 17:45 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely ... Seite 1

Xlife Sciences AG / Key word(s): Letter of Intent/PartnershipXlife Sciences AG paves the way for the next successful out-licensing and announces cooperation with Quant Biomarkers AG for the development of advanced biomarkers for kidney diseases 20.12.2023 / 07:00 CET/CESTXlife Sciences AG (SIX: XLS) and Quant Biomar...

Xlife Sciences AG / Key word: Regulatory Approval Revolutionary AI Algorithm «Prostate.Carcinoma.ai» Achieves EU MDR Class IIa Registration 18-Dec-2023 / 07:00 CET/CEST Release of an...

Xlife Sciences AG / Key word(s): Disposal/Investment Successful exit of portfolio company and major invest in AI and digital health in ...